Relacorilant, 100 mg and 25 mg
CORT125134-553
Phase 3 small_molecule terminated
Quick answer
Relacorilant, 100 mg and 25 mg for Metastatic Pancreatic Ductal Adenocarcinoma is a Phase 3 program (small_molecule) at CORCEPT THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CORCEPT THERAPEUTICS INC
- Indication
- Metastatic Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated